Globus Medical Inc. Class A Common Stock vs iShares Gold Trust — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while iShares Gold Trust trades at $78.05 (market cap $60.87B). The key difference: iShares Gold Trust is far larger — about 5.9× Globus Medical Inc. Class A Common Stock's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, iShares Gold Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and iShares Gold Trust for 51 Days on average.
| GMED | IAU | |
|---|---|---|
Market Cap | $10.25B | $60.87B |
Volume | 1,059,528 | 4,734,029 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $96.82 | $101.57 |
52-Week Low | $58.33 | $74.21 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $9.76B | — |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
IAU shares are trading at $78.25, down 0.11% with bearish technical signals dominating the short-term outlook. The stock faces pressure from rising Treasury yields and Federal Reserve rate uncertainty, though recent soft inflation data has provided some support. Technical indicators show selling pressure outweighing buying signals, with moving averages pointing downward and key resistance at $79.
The stock faces headwinds from monetary policy uncertainty and yield pressures, but potential exists if inflation concerns resurface. Key risks include continued rate hike expectations and dollar strength, while opportunities may emerge from safe-haven demand during market volatility. The technical setup suggests caution in the near term with support at $78.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →